Introduction
Hematopoietic stem cells (HSCs) can self-renew, and differentiate into all types of blood cells throughout life. Mature hematopoietic cells are traditionally categorized into two distinct lineages: the lymphoid and the myeloid. The lymphoid lineage consists of T, B and natural killer (NK) cells, while the myeloid lineage includes a number of morphologically, phenotypically and functionally distinct cell types such as different subclasses of granulocytes (neutrophils, eosinophils and basophils), monocytes-macrophages, erythrocytes, megakaryocytes and mast cells. These two lineages have been thought to use separate differentiation pathways.
HSCs were identified within the 'LSK' (Lin À Sca-1 þ c-Kit þ ) population of the mouse bone marrow (Spangrude et al., 1988; Morrison and Weissman, 1994; Osawa et al., 1996) , and subsequently lineage-restricted progenitors at various developmental stages have been isolated downstream of HSCs by using the multicolor fluorescenceactivated cell sorting system. The successful isolation of the common lymphoid progenitor (CLP) that can generate all lymphoid types but not any myeloid cells, and its counterpart, the common myeloid progenitor (CMP) that can be a source of all myeloid cell types, supports the concept that lymphoid and myeloid lineages develop independently downstream of HSCs Akashi et al., 2000) .
Recent progresses in the fluorescence-activated cell sorting analysis using additional surface markers for early hematopoiesis, however, have provided more detailed developmental map downstream of HSCs. Importantly, prior to proceed into the classical myeloid vs lymphoid pathways, HSCs appear to form myeloerythroid vs myelo-lymphoid progenitors (Arinobu et al., 2007) . Furthermore, it is now clear that there are considerable differences in distribution of surface markers between human and mouse hematopoiesis, which makes identification of human counterparts of mouse progenitors difficult. In this review, we summarize what we have learned from recent studies concerning the developmental sequences in murine and human hematopoiesis.
Developmental pathways in murine hematopoiesis
In murine hematopoiesis, cells with multipotent activity reside in a small fraction of bone marrow, which lacks the expression of lineage-affiliated surface markers (Lin) but expresses high levels of Sca-1 and c-Kit (Spangrude et al., 1988; Ikuta and Weissman, 1992) . Within the LSK population, the most primitive self-renewing HSCs with long-term reconstituting activity (LT-HSCs) reside in the Thy1.1 lo , CD34 À , fms-like tyrosine kinase-3 (Flt3) À or Hoechst low (side population; SP) fraction (Morrison and Weissman, 1994; Osawa et al., 1996; Goodell et al., 1997; Adolfsson et al., 2001 ). The Thy1.1 lo or the CD34 À LSK fraction constitutes only B0.01% of total bone marrow cells. At the single cell level, B20% of Thy1.1 lo or B35% of CD34 À LSK cells display multilineage long-term reconstitution in competitive reconstitution assays (Osawa et al., 1996; Wagers et al., 2002) .
On the other hand, the Thy1.1 and showed some difference in duration and magnitude of reconstitution (Morrison and Weissman, 1994; Morrison et al., 1997) . These reports, however, did not provide clear-cut definition or functional difference of 'ST-HSC' and 'MPP'. We will therefore use MPPs instead of ST-HSCs throughout this review.
The myeloid vs lymphoid pathways downstream of MPP within the LSK fraction Because the LSK population contains all multipotent precursors such as LT-HSCs and MPPs, lineage-restricted progenitor populations were first sought outside the LSK fraction. The CLP is the earliest population that upregulates the receptor for interleukin-7 (IL-7) , an essential cytokine for both T-and B-cell development (Peschon et al., 1994; von Freeden-Jeffry et al., 1995) . The IL-7 receptor signaling plays a critical role in thymocyte survival through maintenance of Bcl-2 , and in the rearrangement of immunoglobulin heavy chain V segments through the activation of the Pax5 gene (Corcoran et al., 1998) . In human, the genetic loss of IL-7Ra chain is found in patients with severe combined immunodeficiency (SCID) (Puel et al., 1998) . The IL-7Ra þ fraction concentrates lymphoid potential in the bone marrow, and IL-7Ra
þ Lin À Sca-1 lo c-Kit lo cells, termed as the CLP, possess clonogenic T-and B-cell, and NK-cell potential, but lack myelo-erythroid differentiation activity .
The CMP was also isolated outside the LSK fraction. . The CMP can generate all types of myeloid colonies, while the GMP or the MEP produces only granulocyte macrophage (GM) or megakaryocyte erythrocyte (MegE) lineage cells, respectively. The CMP differentiates into the GMP and the MEP in vitro, upregulating the FcgRII/III and downregulating the CD34 expression, respectively, indicating that the CMP is the precursor for the GMP and the MEP . Upon in vivo transfer, these populations display short-term production of lineages corresponding to their in vitro activities, indicating that they do not appreciably selfrenew (Na Nakorn et al., 2002) .
The existence of the CLP and the CMP outside the LSK fraction leads to the idea that lymphoid and myeloid development starts at the CLP and the CMP stage, respectively ( Figure 1a ). These stem and progenitor populations are widely used for targeted analysis and manipulation of cells at a specific hematopoietic stage.
Initial hematopoietic lineage commitment starts within the LSK 'MPP' fraction prior to the conventional CMP or CLP stages Although the CMP and the CLP were found outside the LSK fraction, recent studies have revealed that the MPP population is heterogeneous, and contains progenitor subsets committed to myelo-erythroid or myelo-lymphoid lineages (Figures 1b and 2) (Arinobu et al., 2007) .
The question regarding the simple myeloid vs lymphoid diversification model initially arose from the finding that a fraction of MPPs have primed to the lymphoid lineage (Iwasaki and Akashi, 2007) . In mice Hematopoietic developmental pathways H Iwasaki and K Akashi carrying a green fluorescence protein (GFP) gene knocked into the Rag1 gene locus (Kuwata et al., 1999; Igarashi et al., 2001 ), a fraction (B5%) of LSK cells express GFP (Igarashi et al., 2002) . This population, called as the earliest lymphocyte progenitor (ELP), possesses potent T-, B-and NK-differentiation potential with a weak myeloid colony-forming activity (Igarashi et al., 2002) . The original report showed that a few percent of ELPs give rise to GM and rarely MegE colonies. In our hands, the ELP resides within the CD34 þ MPP population (Osawa et al., 1996) , and almost 40% of ELPs can form GM but not MegE colonies (Arinobu et al., 2007) . These data suggest that the ELP population contains cells with GM and lymphoid but not MegE lineage potential. Additional evidence for the myelo-lymphoid commitment within the MPP fraction has been shown by fractionating LSK cells by the expression of Flt3, an HSC-specific receptor tyrosine kinase (Mackarehtschian et al., 1995) . Flt3-deficient mice display loss or reduction of early T, B, NK and dendritic cells (Mackarehtschian et al., 1995; McKenna et al., 2000; Sitnicka et al., 2002) . Mice deficient for Flt3 ligand (FL) lack CLPs, but possess normal numbers of CMPs (Adolfsson et al., 2001) , suggesting that Flt3 signaling plays a critical role in murine lymphoid development. In murine hematopoiesis, Flt3 is not expressed in LT-HSCs, but is upregulated in a fraction of CD34 þ MPPs (Adolfsson et al., 2001; Christensen and Weissman, 2001) . A recent report has shown that Flt3 þ MPPs largely lack MegE potential, whereas they have clonal and robust GM/ lymphoid potential (Adolfsson et al., 2005) , further supporting the concept that LSK cells initially commit to the myelo-lymphoid lineage. This population expresses lymphoid-related Flt3 although still retaining the GM potential, and therefore was termed as the lymphoidprimed multipotent progenitor (LMPP) (Adolfsson et al., 2005) . Although a minor fraction of the LMPP may still retain MegE potential as reported (Forsberg et al., 2006) , the vast majority of the LMPP appears to be committed into the GM/lymphoid lineage.
More recently, further fractionation of the LMPP population was performed by utilizing the expression of vascular cell adhesion molecule-1 (VCAM-1) (Lai and Kondo, 2006) . The Thy1.1 À LSK population, which is almost equal to the CD34 À LMPPs display strong CLP activity in vivo, but similar to the ELP, around 10% of VCAM-1 À LMPPs give rise to GM, but not MegE colonies (Lai and Kondo, 2006) . Thus, like ELPs, the majority of VCAM-1 À LMPPs have committed to the lymphoid lineage, but a fraction of them likely have GM/lymphoid potential. This study describes the heterogeneity of the LMPP, but basically supports the concept that toward the lymphoid lineage development, the loss of myeloid potential occurs first in the MegE and then in the GM lineage (Akashi et al., 2005) .
Myelo-erythroid vs myelo-lymphoid diversification at the 'MPP' stage can be visualized by utilizing transcription-factor reporters The limitation of the surface-marker-based fractionation is that the upregulation or downregulation of surface markers should occur as a result of lineage decision: Lineage-restricted progenitors have been purified based on the difference in the expression level of antigens that may not have significant functions in lineage fate decision, such as Sca-1, CD34 and Thy1. Recent data have shown that more rigorously committed progenitors are isolatable by the aid of transcription-factor reporters. A high-resolution map containing new lineage-restricted progenitor populations within the LSK MPP fraction has been obtained by utilizing mice having PU.1 or GATA-1 transcriptional factor reporters ( Figure 2 ) (Arinobu et al., 2007) . PU.1 and GATA-1 transcription factors exert instructive signals for GM and MegE lineage commitment, respectively (Kulessa et al., 1995; Nerlov and Graf, 1998; Seshasayee et al., 1998; Heyworth et al., 2002; Iwasaki et al., 2003) . PU.1 transactivates a number of GM-and lymphoid-related genes (Zhang et al., 1996; DeKoter et al., 1998 DeKoter et al., , 2002 Iwama et al., 1998) , and is necessary for generation of early GM and lymphoid progenitors such as CMPs, GMPs and CLPs (Iwasaki et al., 2005b) , whereas GATA-1 is an essential transcription factor for MegE development (Fujiwara et al., 1996) . Furthermore, PU.1 and GATA-1 mutually inhibit each other's expression and transactivation functions (Nerlov and Graf, 1998; Rekhtman et al., 1999; Zhang et al., 1999 Zhang et al., , 2000 Nerlov et al., 2000; Walsh et al., 2002) . On the basis of these findings, the competitive interplay of PU.1 and GATA-1 might play a critical role in early hematopoietic fate decision such as the GM or lymphoid vs the MegE lineage commitment (Graf, 2002; Iwasaki and Akashi, 2007) .
The expression of PU.1 and GATA-1 reporters within the LSK fraction was tested together with the expression of Flt3, the critical marker for the LMPP (Arinobu et al., 2007) . Murine long-term HSCs do not express Flt3 (Adolfsson et al., 2001; Christensen and Weissman, 2001) . In a mouse line harboring the GFP gene knocked into the PU.1 locus (Back et al., 2005) , CD34
À long-term HSCs are entirely Flt3 À and PU.1-GFP lo (PU.1 lo ) (Iwasaki et al., 2005b) . A high level of PU.1-GFP is expressed in a fraction of CD34 þ MPPs expressing a high level of Flt3, suggesting that this population represents the earliest hematopoietic stage initiating PU.1 upregulation. In contrast, in a mouse line having the transgenic GATA-1 reporter tagged with GFP (Iwasaki et al., 2005a) MPPs is the earliest, potent CMP within the LSK fraction. Thus, the CD34 þ MPP population expressing PU.1 or GATA-1 reporters represents granulocytemonocyte-lymphoid progenitors (GMLPs) or CMPs, respectively (Arinobu et al., 2007) .
The new developmental model is schematized in Figure 1b . In this model, HSCs express low PU.1, perhaps to maintain self-renewal activity (Iwasaki et al., 2005b) . The subsequent upregulation of GATA-1 occurs in a fraction of CD34 þ MPPs to establish the bipotent CMP stage where GATA-1 and PU.1 are primed to play a competitive interaction , whereas the upregulation of PU.1 results in the formation of the GMLP. Then, when PU.1 becomes more dominant, the CMP and the GMLP (or the LMPP) give rise to GMPs plus CLPs, whereas when GATA-1 becomes dominant, CMPs produce MEPs at the expense of GMPs. Thus, the reciprocal activation of GATA-1 and PU.1 primarily organizes hematopoietic lineage fate decision to form the earliest hematopoietic branchpoint that comprises isolatable myelo-erythroid and myelo-lymphoid progenitor populations (Arinobu et al., 2007) .
Importantly, the new model allows flexibility for GM development as the GMP can be generated from both the GMLP and the CMP stages within the LSK fraction. The GMP is the source of a number of myeloid subclasses because it is capable of producing all granulocyte progenitors such as eosinophil progenitors, basophil progenitors, basophil-mast cell progenitors (BMCPs) and mast cell progenitors (MCPs) (Arinobu et al., 2005; Iwasaki et al., 2005a Iwasaki et al., , 2006 . The detailed developmental scheme and its molecular mechanisms downstream of the GMPs are summarized in our recent review (Iwasaki and Akashi, 2007 (Igarashi et al., 2002) , whereas CLPs and CLP-2 are isolated based on a high level of IL-7Ra expression. In the steady-state thymus, the c-Kit þ early T-cell progenitor fraction (Allman et al., 2003) is the earliest thymic precursor (ETP), and this population express only negative to low levels of IL-7Ra. These data have been interpreted that the ELP is upstream of the CLP and the CLP-2 (Bhandoola and Sambandam, 2006) .
To formally test the lineal relationship between the ELP and the CLP, the history of RAG1 activation is tracked by using a RAG1 'ancestory' mouse (unpublished data), applying the similar strategy used to track the history of lysozyme M gene transcription (Ye et al., 2003) . The mouse line harboring the Cre recombinase knocked into the RAG1 locus was established, and was crossed with the ROSA26 yellow fluorescence protein (YFP) reporter mouse line. In this line, the Cre recombinase is activated in parallel with the endogenous activation of RAG1 transcription, and once RAG1 is activated, cells are permanently labeled with YFP. The majority of CLPs are negative for RAG1-Cre/YFP. Only RAG1-Cre/YFP À CLPs give rise to T as well as B and NK cells in vivo, although RAG1-Cre/YFP þ CLPs give rise only to B and NK cells, indicating that true CLPs do not have a history of RAG1 activation. Furthermore, the RAG1-Cre/YFP À CLP rapidly acquires ETP phenotype under thymic microenvironment after intrathymic injection (unpublished data). These data suggest that the CLP is not a population downstream of the ELP, but represents the T-cell pathway independent of the ELP. Since the GMLP can generate at least the CLP (Arinobu et al., 2007) , the divergence of the CLP and the ELP probably occurs at the GMLP stage. The developmental scheme for the lymphoid lineage based on these data is shown in Figure 3 .
Upon seeding the thymus, bone marrow progenitors have to enter in the circulation. The LMPP, the ELP and the CLP are detectable in peripheral blood, whereas the CLP-2 has not been found in the blood (Schwarz and Bhandoola, 2004; Perry et al., 2006; Krueger and von Boehmer, 2007; Umland et al., 2007) . Recently, a novel T-lineage-committed progenitor subset presumably downstream of the CLP-2 was found in adult murine blood. This circulating T-cell progenitor is isolatable by unique phenotype of Lin
, and is distinguishable from other lymphoid progenitors (for example, LMPP, ELP, CLP or CLP-2) by the absence of Flt3 expression (Krueger and von Boehmer, 2007) . The circulating T-cell progenitor differentiates into only T and NK cells, but not into B or myeloid cells. Thus, T and B cells could be derived from these multiple, independent lymphoid progenitor populations. It is critical to test the lineal relationship among these populations and their relative contribution toward T-and B-cell homeostasis by performing competitive reconstitution analysis, for example.
Developmental pathways in human hematopoiesis
The expression patterns of surface markers specific for hematopoietic stem and progenitor populations are considerably different between human and mouse. Importantly, mouse LT-HSCs are CD34 À/lo (Osawa et al., 1996) , CD38
þ (Randall et al., 1996) and CD90 (Thy1) lo (Spangrude et al., 1988; Morrison and Weissman, 1994) , whereas human HSCs are hCD34 þ (Okuno et al., 2002) , hCD38
À (Terstappen et al., 1991; Ishikawa et al., 2003) Sca-1 c-Kit þ GMLPs might be the precursor for ELPs and CLPs. pTa þ CLP-2 might be derived from the CLP. These populations home the thymus to generate T cells via the earliest thymic precursor (ETP), or produce B cells in the bone marrow. The relative contribution of these progenitors toward lymphoid development is still unclear. CLP, common lymphoid progenitor; ELP, earliest lymphocyte progenitor; GMLP, granulocyte-monocyte-lymphoid progenitor; HSC, hematopoietic stem cell.
and hCD90
þ (Baum et al., 1992) . The fact that mouse LT-HSCs in steady-state bone marrow do not express significant levels of mCD34 (Osawa et al., 1996) raised an important question of whether hCD34 þ cells could mark all long-term self-renewing human HSCs. Mouse lines harboring human genomic P1 artificial chromosome (PAC) clones containing the entire hCD34 gene, including all exons, introns and more than 18 kb of 5 0 -and 3 0 -flanking sequences were established (Okuno et al., 2002) . In all transgenic mouse strains, mCD34 À/lo LSK LT-HSCs expressed the hCD34 transgene. In progenitor populations, the hCD34 transgene was expressed in the majority of CLPs, CMPs and GMPs, and B30% of MEPs (Okuno et al., 2002) . These data strongly support the notion that hCD34 þ human bone marrow cells contain the vast majority of LT-HSCs, as well as primitive myeloid and lymphoid progenitors.
The long-term reconstitution potential of human HSCs has been directly shown in SCID mouse repopulating assays. In the most advanced xenotransplant models by utilizing the Rag2 and IL-2Rg doubledeficient mouse (Traggiai et al., 2004) or the NOD-SCID IL2Rg deficient mouse (Ishikawa et al., 2005) , hCD34 þ hCD38 À or the hCD34 þ hCD90 þ fractions of human bone marrow and cord blood can reconstitute all human hematolymphoid lineage cells for a long term, indicating that these hCD34 þ fractions contains normal human HSCs. However, it is still questionable that these xenotransplant models correctly recapitulate the settings of the congenic murine transplant or the clinical human HSC transplant. For example, although mouse CD34 À HSCs reconstitute congenic animals for a long term even at the single cell level, injection of at least 1000 cells of the human hCD34 þ hCD38 À bone marrow cells is required to obtain multi-lineage, long-term reconstitution in xenotransplant models. Thus, it is unknown whether the HSC that is capable of reconstitution of all lineages at the single cell level exists in human hematopoiesis, and if so, what percent of hCD34 þ hCD38
þ cells are multipotent, longterm HSCs.
Human lymphoid and myeloid progenitor subsets within the hCD34 þ hCD38 þ MPP fraction Galy et al. (1995) first reported the existence of lymphoidcommitted progenitors in the human bone marrow with the hCD34 þ hCD38 þ hCD45RA þ hCD10 þ phenotype. Lymphoid potential was determined by reconstitution of human bone and thymus fragments implanted into SCID mice as well as by in vitro culture systems. Limiting dilution assays suggested that this population contains clonal progenitors of B, NK and DC lineages (Galy et al., 1995) . In human cord blood, CLP activity is found in the hCD7 (Hao et al., 2001) . Interestingly, the hCD7
þ population does not exist in the adult bone marrow (Hao et al., 2001) . IL-7Ra, a critical marker for the murine CLP, is expressed in human hCD10
þ CLPs in the bone marrow, but not in hCD7 þ CLPs in the cord blood. These data suggest that the CLP phenotype and the requirement of IL-7 signaling may change during human ontogeny. In the myelo-erythroid pathway, CMP, GMP and MEP subsets are isolatable within the hCD34 þ hCD38 þ fraction in both the bone marrow and cord blood (Manz et al., 2002) . All are negative for the early lymphoid markers hCD10, hCD7 or hIL-7Ra. These myeloerythroid progenitors are prospectively isolatable according to the expression of hCD45RA and hIL-3Ra. hCD45RA
À hIL-3Ra lo (CMPs), hCD45RA þ hIL-3Ra lo (GMPs) and hCD45RA À hIL-3Ra À (MEPs) efficiently formed distinct myelo-erythroid colony types according to their definitions. CMPs give rise to MEPs and GMPs in vitro, and a significant proportion of CMPs possess clonal GM and MegE potentials (Manz et al., 2002) . Thus, the hierarchical myeloid progenitor relationships demonstrated in mice is well preserved in human hematopoiesis. Phenotypic comparisons between mouse and human subsets show that CD34, a marker positive for only murine CMPs and GMPs, is uniformly expressed on all three human subsets, and that the FcgRII/III (CD16/CD32), marking murine CMPs and GMPs, was not detectable in none of human myeloid progenitors (Manz et al., 2002) .
All of these hematolymphoid progenitors develop from hCD34 þ hCD38 À HSC population (Ishikawa et al., 2005) , but themselves have no self-renewal activity in xenogeneic transplantation models (Ishikawa et al., 2007) , indicating that they are downstream of human LT-HSCs in both the bone marrow and the cord blood.
The human counterpart for murine LMPP or GMLP have not been identified in human hematopoiesis Another critical difference between human and mouse hematopoiesis is the expression pattern of Flt3. Around 40-80% of hCD34 þ bone marrow and cord blood cells express hFlt3 (Rappold et al., 1997; Sitnicka et al., 2003) . Although a fraction of both the hFlt3 þ and the hFlt3 À populations gave rise to multilineage colonies containing all myelo-erythroid components, the hFlt3 þ hCD34 þ and hFlt3 À hCD34 þ populations predominantly formed GM and erythroid colonies, respectively (Rappold et al., 1997; Gotze et al., 1998; Sitnicka et al., 2003) , and cells with NOD-SCID reconstitution activity reside in the hCD34 þ hFlt3 þ fraction (Sitnicka et al., 2003) . Our recent experiments have revealed that hFlt3 is expressed in the entire human bone marrow and cord blood hCD34 þ hCD38 À population, and purified hFlt3 þ hCD34 þ hCD38 À cells could reconstitute multilineage cells for a long term in the NOD-SCID/ IL-2Rgnull xenogeneic transplantation system (unpublished data). Therefore, unlike mouse hematopoiesis, human LT-HSCs express hFlt3. Furthermore, in striking contrast to mouse hematopoiesis where Flt3 is expressed in CLPs but not GMPs (D'Amico and Wu, 2003; Karsunky et al., 2003) , hFlt3 is expressed in GMPs as well as in CLPs at a high level in human hematopoiesis (unpublished data). Thus, the hFlt3 expression does not mark lymphoid-primed progenitor populations in human. The significant difference of Flt3 distribution in human and mouse hematopoiesis suggests that the critical role of Flt3 signaling in hematopoietic development could also be different. hFlt3 is expressed in leukemic blasts in most cases with acute myelogenous leukemia (AML) (Carow et al., 1996; Rosnet et al., 1996) , and FLT3 is one of the most frequently mutated genes in AML (Gilliland, 2002; Stirewalt and Radich, 2003) . The FLT3 mutants transduce constitutively active Flt3 signaling, which could be the cause of poor prognosis in AML with FLT3 mutations (Kiyoi et al., 1999; Schnittger et al., 2002; Thiede et al., 2002) . Because the signal from FLT3 mutations should be controlled under the regulation of normal Flt3 expression machinery, signaling from FLT3 mutations should involve HSCs and GMPs, both of which are critical targets for leukemic transformation in mouse AML models (see the next section) So et al., 2003; Huntly et al., 2004; Wang et al., 2005) . Thus, special considerations are required in utilizing mouse models to understand the role of FLT3 mutations in human leukemogenesis.
In summary, although the hierarchical precursorprogeny relationships observed in mouse hematopoiesis appear to be generally preserved in human, expression patterns of a number of surface antigens at each developmental stage are significantly different between human and mouse, and hematopoietic progenitors restricted to GM-lymphoid lineage have not been identified in human hematopoiesis.
Cellular targets in leukemogenesis
Leukemias appear to depend on a small population of 'leukemic stem cell (LSC)' for their continued growth and propagation Huntly and Gilliland, 2005) . The origin of LSCs is controversial, and their phenotype and biology is still not fully elucidated. The LSC is likely to be a crucial cellular target in the treatment of leukemias, and therefore, it is critical to understand difference of cellular properties between LSCs and normal HSCs.
A variety of mouse AML models have been shown that AML can develop from either HSCs or progenitor populations lacking self-renewal capability. The MRP8 gene encodes a small calcium-binding protein of the S100 family, which is only expressed in CMPs and GMPs, but not in HSCs (Jaiswal et al., 2003) . By enforcing the expression of leukemia-specific fusion genes under the control of the human MRP8 promoter, a number of AML models have been established: MRP8-BCR-ABL transgenic mice develop a CML-like disease with occasional progression into AML (Jaiswal et al., 2003) , MRP8-PML-RARa transgenic mice exhibit a preleukemic state, which eventually progresses to APL (Brown et al., 1997; Kogan et al., 2001) , and MRP8-AML1-ETO transgenic mice develop AML with high frequency after mutagenesis treatment (Yuan et al., 2001) . These studies suggest that the enforced expression of leukemia fusion genes at the CMP or GMP stage is sufficient for progenitors to acquire self-renewal activity to develop into the LSC. More directly, retroviral transduction of leukemia fusions including MLL-ENL , MLL-AF9 (Krivtsov et al., 2006) and MOZ-TIF2 (Huntly et al., 2004) could confer LSC property in self-renewing HSCs as well as non-selfrenewing CMPs-GMPs. Thus, at least these leukemic fusion proteins can induce leukemic transformation at the level of myeloid progenitors without involving HSCs. However, in a practical scenario of spontaneously arising human leukemia, it appears that HSCs accumulate the leukemogenic mutations, and that these genetic mutations exert their effects at the progenitor stage, leading to the generation of LSCs downstream of the HSCs.
The human LSC population capable of repopulating AML in the NOD-SCID mouse model has the hCD34 þ hCD38
À normal HSC phenotype (Bonnet and Dick, 1997 (Jordan, 2002) . For example, in the majority of AML cases, LSCs do not express hCD90 , but express a high level of IL-3Ra (Jordan et al., 2000) and hCD45RA (unpublished data), resembling the phenotype of normal human GMPs. Therefore, it is also possible that human AML LSCs may arise from GMPs but lose the expression of hCD38 when they become LSCs. Similarly, at least in a fraction of acute lymphoblastic leukemia (ALL), LSCs possess the hCD34 þ hCD38 À phenotype but express hCD19 (Castor et al., 2005) .
As in mouse studies, it should be critical to elucidate the cellular target for LSC formation by the targeted transduction of leukemia-specific fusion genes into purified human HSCs or progenitors, and by testing whether such treatment recapitulate the transformation process of human leukemia. A recent study has shown that the retroviral transduction of MLL-ENL or MLL-AF9 into human bone marrow cells can establish AML or ALL in NOD-SCID mouse recipients (Barabe et al., 2007) . Although the efficiency of gene transduction into human hematopoietic cells appears to be still unsatisfactory, this type of experimental approach should be useful to clarify more detailed developmental mechanisms of human leukemias in future studies.
Conclusion
The ability to prospectively isolate lineage-restricted progenitors has greatly helped us understand the hematopoietic developmental pathway from HSCs in both mouse and human hematopoiesis. It is now clear that murine HSCs choose the myelo-lymphoid or the myelo-erythroid pathway to develop hematolymphoid progeny, and therefore the GM lineage cells can develop either of these pathways. The surface phenotype of human hematopoietic stem and progenitor cells is quite different from those in mice. Further phenotypic and functional characterization of human hematopoietic cells should be performed by utilizing improved efficient xenotransplant models. These approaches will eventually help to identify LSCs that should be a critical cellular target in leukemia treatment.
